I didn't think we had any proprietary rights to the Bio-Marker test, but we definitely have the rights to use the test....and the test works great to predict non-responders so they do not need to develop any other companion diagnostic test at this point. What is important is that we have this proven test that will select the right people for the planned registration trial. IR seems very confident in proceeding with a registration trial. IR has been very curtious with their responses and I feel that they already know the data is good enough to proceed to the next phase.
News 
Market Data 
Discover 
AI
